Neuroendocrine cancer of the prostate is a rare and aggressive form of prostate cancer that can develop when cancer cells stop responding to typical hormone treatments. While less than 2% of all prostate cancers are of this type, understanding this condition is crucial for those facing the challenge of advanced prostate cancer, as it behaves quite differently from the more common types of the disease.

Understanding How Often This Cancer Occurs

Neuroendocrine cancer of the prostate, often called NEPC, is considered a rare condition in the larger picture of prostate cancer cases. When doctors diagnose prostate cancer for the first time, less than 2% of these cases show features of neuroendocrine cancer right from the start.^[2] This initial form is known as de novo neuroendocrine prostate cancer, meaning it appears without any previous history of typical prostate cancer.

However, recent research has revealed a more concerning pattern. Among men who have already been diagnosed with prostate cancer that has spread beyond the prostate and no longer responds to hormone therapy, nearly one in five may develop this aggressive subtype.^[8] This is actually more common than doctors previously thought. A study examining tumor samples from 160 men with advanced, treatment-resistant prostate cancer found that 17% had developed the neuroendocrine subtype.^[8] This transformation can happen after patients receive potent hormone-blocking medications like abiraterone or enzalutamide, which are standard treatments for advanced prostate cancer.

What makes this particularly important is that this percentage suggests many more patients than previously estimated are dealing with this challenging form of the disease. The condition typically affects men who have been living with prostate cancer for some time, particularly those whose cancer has become resistant to multiple lines of treatment.^[10]

What Causes This Type of Cancer to Develop

The development of neuroendocrine prostate cancer is deeply connected to how cancer cells adapt and survive when faced with treatments designed to stop them. Normal prostate tissue contains a small population of special cells called neuroendocrine cells, making up approximately 1% of all cells in the prostate gland.^[2] These cells have unique characteristics, sharing traits with both nerve cells that send signals and endocrine cells that produce hormones.^[7]

In most cases, neuroendocrine prostate cancer doesn’t start that way. Instead, it develops through a process scientists call lineage plasticity. This complicated term describes how prostate cancer cells essentially change their identity to survive.^[1] When patients receive hormone treatments that block androgen receptor signaling—the pathway that typically fuels prostate cancer growth—some cancer cells find a workaround. Rather than dying, they transform into a different type of cell that doesn’t need androgen hormones to survive and grow.^[1]

This transformation is made possible by specific genetic changes within the cancer cells. Research has identified that loss of two important tumor suppressor genes, called RB1 and TP53, acts as a key facilitator of this cell identity change.^[1] When these protective genes stop working properly, cancer cells gain the flexibility to adopt alternative survival programs. The process also involves significant changes in how genes are turned on or off, controlled by epigenetic modifications—chemical changes that don’t alter the DNA sequence itself but change how genes are expressed. For example, overexpression of a protein called EZH2 and alterations in DNA methylation patterns drive tumor cells to express neuronal and neuroendocrine characteristics.^[1]

Who Is Most at Risk

The risk of developing neuroendocrine prostate cancer is particularly elevated in men who have already been battling advanced prostate cancer for an extended period. Men whose cancer has become resistant to standard hormone treatments, a condition known as castration-resistant prostate cancer (CRPC), face the highest risk.^[1] This is especially true for those who have received treatment with newer, more potent anti-androgen medications like abiraterone acetate or enzalutamide.^[8]

The longer a patient remains on these hormone-blocking therapies, the more opportunity cancer cells have to adapt through the lineage plasticity process. Essentially, the very treatments that initially work so well at controlling prostate cancer can, over time, create pressure that drives some cancer cells to transform into the neuroendocrine subtype as a survival mechanism.^[10]

Men whose cancer has already spread to multiple sites in the body, particularly to bones, lymph nodes, liver, or other soft tissues, are also at increased risk. Research has shown that the neuroendocrine transformation can occur in metastatic tumors regardless of their anatomical location.^[8] Additionally, patients whose tumors show specific genetic characteristics, particularly loss of the RB1 and TP53 tumor suppressor genes, appear to be more vulnerable to developing this aggressive subtype.^[1]

It’s worth noting that while most cases develop in men with a history of treated prostate cancer, a small percentage of men are diagnosed with neuroendocrine prostate cancer from the very beginning, without any prior prostate cancer diagnosis. This de novo form can affect men at various ages, though prostate cancer in general is more common in men aged 50 to 60 years and older.^[18]

Recognizing the Symptoms

The symptoms of metastatic neuroendocrine prostate cancer can be quite different from those of typical prostate cancer, partly because this subtype behaves more aggressively and spreads differently. One notable characteristic is that men with neuroendocrine prostate cancer often have normal or only slightly elevated levels of PSA (prostate-specific antigen), a protein typically measured to monitor prostate cancer.^[8] This happens because neuroendocrine cancer cells lose their dependence on androgen receptor signaling, which normally drives PSA production. As a result, PSA levels may not accurately reflect the presence or progression of disease, which can make the cancer harder to detect using standard monitoring methods.

Because this type of cancer tends to grow and spread rapidly, symptoms often relate to where the cancer has metastasized in the body. When cancer spreads to the liver, patients may experience abdominal discomfort, loss of appetite, unexplained weight loss, or jaundice (yellowing of the skin and eyes). Bone metastases can cause deep, persistent bone pain, increased risk of fractures, or spinal cord compression if tumors grow in the spine. Spread to the lymph nodes may cause swelling in various parts of the body.

General symptoms related to advanced cancer may include fatigue that doesn’t improve with rest, significant weight loss without trying, and overall weakness that affects daily activities. Some patients may experience neurological symptoms if the cancer spreads to the brain or nervous system, such as confusion, headaches, or difficulty with coordination. The aggressive nature of this cancer means symptoms often develop relatively quickly and progress more rapidly than with typical prostate adenocarcinoma.

How This Cancer Can Be Prevented or Detected Earlier

Preventing neuroendocrine transformation of prostate cancer remains a significant challenge because the process is closely tied to how cancer cells adapt to treatment pressures. Currently, there is no proven strategy to completely prevent this transformation in men receiving hormone therapy for advanced prostate cancer. However, researchers are actively studying the biological processes that lead to lineage plasticity to develop interventions that might block this pathway.^[10]

What can be improved is the earlier detection of this subtype when it does develop. Traditionally, doctors have recommended tumor biopsies primarily for patients showing specific warning signs, such as spread to the liver or rapidly worsening disease despite normal PSA levels. However, given that nearly one in five men with treatment-resistant metastatic prostate cancer may have the neuroendocrine subtype, experts now suggest that broader testing should be considered.^[8]

When neuroendocrine prostate cancer is suspected or confirmed, this diagnosis can lead to important changes in treatment strategy. Rather than continuing with hormone-based therapies that are unlikely to work, patients can be switched to chemotherapy regimens that are more appropriate for this type of cancer. Early detection of the transformation therefore allows for more timely and potentially more effective treatment adjustments.

For men already diagnosed with advanced prostate cancer, staying alert to changes in their condition is important. If cancer appears to be progressing despite treatment, particularly if PSA levels remain low or stable while symptoms worsen, discussing the possibility of tumor biopsy with healthcare providers may be valuable. The biopsy can examine cells under a microscope to determine if neuroendocrine features are present, which requires expert pathology review to accurately distinguish from typical prostate cancer.^[2]

What Happens in the Body

Understanding what happens inside the body when prostate cancer transforms into the neuroendocrine subtype helps explain why this form is so aggressive and why it responds differently to treatments. The fundamental change involves how cancer cells function and what drives their growth.

In typical prostate cancer, cells depend heavily on androgen receptor (AR) signaling. Androgens are male hormones like testosterone that bind to androgen receptors in prostate cells, triggering signals that tell cells to grow and divide. This is why hormone-blocking treatments work so well initially—they cut off this critical growth signal. However, in neuroendocrine prostate cancer, cells undergo a dramatic shift. They lose their dependence on androgen receptor signaling, which is reflected in the downregulation of AR itself, along with PSA and PSMA (prostate-specific membrane antigen), proteins normally present in prostate cancer cells.^[1]

This independence from androgens means the cancer no longer needs testosterone or similar hormones to survive and multiply. The cells essentially rewire their internal machinery to grow through completely different pathways. They begin expressing genes and proteins typically seen in neuroendocrine cells and neural (nerve) tissue, which is why this cancer is called “neuroendocrine.” This switch is controlled in part by special transcription factors—proteins that act like molecular switches—including SOX2, ASCL1, and BRN2, which drive the expression of neuronal and neuroendocrine characteristics.^[1]

The transformation process is not just about gaining new features; it also involves losing normal control mechanisms. The loss of tumor suppressor genes RB1 and TP53 removes critical brakes on cell division and survival, allowing cells to proliferate unchecked and resist the body’s normal mechanisms for eliminating abnormal cells.^[1] Meanwhile, epigenetic changes—modifications to how DNA is packaged and read—further drive the transformation. For instance, overexpression of EZH2, a protein involved in gene regulation, and alterations in DNA methylation patterns contribute to shutting down prostate-specific genes while activating neuroendocrine programs.^[1]

Importantly, treatment-related neuroendocrine prostate cancer develops from the same original cancer cells, not as a completely separate new cancer. Studies have shown that it arises clonally, meaning it comes from the original prostate adenocarcinoma, retaining early genomic events while acquiring new molecular features.^[10] This is why, when examined carefully, neuroendocrine tumors still carry some of the genetic fingerprints of the original prostate cancer, alongside the new changes that define the neuroendocrine phenotype.

The end result of all these changes is a cancer that grows rapidly, spreads aggressively, and doesn’t respond to the hormone-based therapies that work against typical prostate cancer. The cells have essentially evolved a completely different strategy for survival, which requires a fundamentally different treatment approach.